Treatments - Medika Life

The FDA approves Aduhelm for the treatment of early Alzheimer's disease. Aduhelm targets brain plaque formation to slow the rate of cognitive decline.

Based on the available scientific evidence and current clinical experience, the SPR Collaboration recommends that physicians and authorities consider the following Covid-19 treatment protocol for the early treatment of people at high risk or high exposure

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

Health Innovation Has a Friction Problem

India: The Growing Focal Point for Health Innovation

Jackie Kennedy and Jane Fonda — Same Diagnosis, Different Decades and Treatments

Ivermectin is Dead and Buried Despite NIH Website Misstep and Twitter Buzz

LATEST

TRENDING

Jackie Kennedy and Jane Fonda — Same Diagnosis, Different Decades and Treatments

Ten Facts You Didn’t Know About Moderna and Their mRNA Vaccine

Ivermectin is Dead and Buried Despite NIH Website Misstep and Twitter Buzz

Killing The Coronavirus. A New Treatment Shows 99.9 Percent Efficacy

Oriahnn; A Drug to Stop Heavy Periods for Women With Fibroids

Is mRNA Technology the New Penicillin?

The Nation’s Only Virtual At-Home Detox Programs from Workit Health Expands

Artificial Intelligence Company Helps IVF Patients Get Pregnant

FDA Approval of New Drug for Alzheimer’s Offers Hope

Parnell Pharmaceuticals Announces Nomovid™ Antiviral Nasal Spray

EDITORS CHOICE

India: The Growing Focal Point for Health Innovation

The Fluoroscope Serves as a Warning for New Medical Technology

FDA Approval of New Drug for Alzheimer’s Offers Hope

On the treatment of Covid-19

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories